Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY

https://doi.org/10.20996/1819-6446-2010-6-1-29-36

Full Text:

Abstract

Aim. To study antihypertensive efficacy and safety of valsartan (Diovan, Novartis Pharma) as well as patient’s compliance to the mono- or combined valsartan based therapy in smoking vs non-smoking hypertensive patients.

Material and methods. It was a prospective multicenter observation study. 114 doctors from 81 medical institutions of Russia participated in the study. 650 hypertensive patients (41,2% of smokers and 58,8% of non-smokers; age 53,9±0,4 y.o. in average) were included in the study. The evaluation of therapy efficacy was based on analysis of systolic (SBP) and diastolic (DBP) blood pressure (BP) changes and of patient number who answered to the treatment and reached BP target level. Safety and compliance of the treatment also was analyzed. The initial valsartan dose was 80 mg OD and may be increased (up to 320 mg OD) by doctor for achievement of BP target level. A combination of the valsartan with hydrochlorothiazide was also allowed. Amlodipine (5-10 mg/d) or any other antihypertensive also may be added if necessary.

Results. Significant decrease of SBP and DBP was observed in each group between the 1st and 5th visits. SBP decreased by 37,5 mm Hg (р<0,01) in smoking patients and by 37,6 mm Hg (р<0,01) in non-smoking ones. DBP decreased by 18,5 mm Hg (р<0,01) in smoking patients and by 15,9 mm Hg (р<0,01) in non-smoking ones. Differences in SBP and DBP changes were not significant between groups. Target BP level (<140/90 mm Hg) was reached in 96,2% of smokers and in 96% of non-smokers. 99% of smoking patients and 96,1% of non-smoking ones responded to valsartan based therapy according to defined criteria.

Conclusion. Similar antihypertensive efficacy and safety of valsartan mono- and combined therapy was found out in smoking and non-smoking hypertensive patients.

About the Authors

V. I. Podzolkov
Moscow Medical Academy named after I.M.Setchenov
Russian Federation
Bolshaya Pirogovskaya ul. 6, Moscow, 119991


V. A. Bulatov
Novartis Pharma
Switzerland
WSJ-27.4.37, Basel CHBS-4002


A. V. Vigdorchik
Novartis Pharma
Russian Federation
Sadovnicheskaya ul. 82, stroen. 2, Moscow 115035


References

1. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217-23.

2. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006;(4):45-50.

3. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008;7(6 приложение 2):1-32.

4. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72.

5. Mancia G.,De Backer G.,DominiczakA. et al. 2007 Guidelines forthe Management of Arterial Hypertension: The Task Force fortheManagement of ArterialHypertension ofthe European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.

6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421.

7. Bobak M., Gilmore A., McKee M. et al. Changes in smoking prevalence in Russia, 1996-2004. Tob Control 2006;15(2):131-5.

8. Schnoll R.A., Engstrom P.F., Subramanian S. et al. Prevalence and correlates of tobacco use among Russian cancer patients: implications for the development of smoking cessation interventions at a cancer center in Russia. Int J Behav Med 2006;13(1):16-25.

9. Kyvelou S.M., Vyssoulis G.P., Karpanou E.A. et al. Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflam￾mation indices: the effect of smoking. J Clin Hypertens (Greenwich) 2007;9(1):21-7.

10. Reims H.M., Oparil S., Kjeldsen S.E. et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004;13(6):376-84.

11. Hermida R.C., Calvo C., Ayala D.E. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003;42(3):283-90.

12. Hermida R.C., Calvo C., Ayala D.E. et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005;23(10):1913-22.

13. Calvo C., Hermida R.C., Ayala D.E. et al. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22(4):837-46.

14. Fogari R., Mugellini A., Zoppi A. et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: Adouble-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Current Therapeutic Research 2002;63(1):1-14.

15. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906.

16. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascularrisk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.

17. Zanchetti A., Julius S., Kjeldsen S. et al. Outcomes in subgroups of hypertensive patients treatedwith regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006;24(11):2163-8.

18. Cohn J.N., Tognoni G.Arandomized trial ofthe angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23): 1667-75.

19. Mochizuki S., Dahlof B., Shimizu M. et al. Valsartan in a Japanese populationwith hypertension and other cardiovascular disease (JikeiHeart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369(9571):1431-9.

20. Sawada T., Yamada H., Dahlof B. et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30(20):2461-9.

21. Bloom B.S. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20(4):671-81.

22. Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58(3):177-80.

23. Fogari R., Zoppi A., Poletti L. et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14(1):27-31.

24. Fogari R., Preti P., Zoppi A. et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004;17(1):77-81.


For citation:


Podzolkov V.I., Bulatov V.A., Vigdorchik A.V. ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY. Rational Pharmacotherapy in Cardiology. 2010;6(1):29-36. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-29-36

Views: 429


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)